Chat with us, powered by LiveChat

Loading...

Tissue Diagnostics Market Report

RA00245

Tissue Diagnostics Market, by Technology (ISH, digital pathology, anatomy pathology, work flow, consumables), Application (Breast cancer, prostate cancer, gastric cancer, non-small cell lung cancer, others), End User (Hospitals, Research Laboratories, Pharmaceutical Organizations, Research Organizations), Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2020–2027

RA00245

Pages: NA

Jun 2020

COVID-19

pandemic has shown to have an enormous impact on most
industries.

Click Here to access our comprehensive analysis of the

Impact of covid-19 on Tissue Diagnostics Market

Tissue diagnostics is a complete understanding and documenting about a tissue that was obtained. Also, it can be defined as a tissue collected for diagnosing and observing its overall measurement and description and observing if any abnormality exists. With the use of tissue diagnostics, we can know the status of a patient’s health condition and any diseased state. It can be conducted through mail processes like scanning, slide staining, in situ hybridization (ISH), and other techniques.

Tissue Diagnostics Market Analysis:

The tissue diagnostics is most fundamentally utilized for lymphoma, breast cancer, carcinoma, prostate malignant growth, and gastric malignant growth. Among these, breast cancer is dominating the tissue diagnostics market attributable to rising oncological conditions in developed and developing nations. As indicated by the World Health Organization, 2.1 million people acquire breast cancer every year, and 627,000 have demised out of the breast cancer, in 2018.

Increased cancerous conditions globally and the need for technological advancements are the driving factors for the market in the estimated period.

An increase in the number of cancer conditions globally, which is causing the need for better features, and advanced technology will drive the market in the estimated period. An increase in healthcare expenditure is predicted to drive the market in the forecast period. The increased focus by the market leaders in developing advanced level tissue diagnostic-based text will drive the revenue generation in the tissue diagnostics market.

High cost for installation and lack of penetration into developing countries are the major hindrances for the growth of the market in the forecasted period.

Higher cost for installing the systems and higher penetration in the developing countries is predicted to hamper the market in the forecast period. There is a strict regulatory framework for new product approval and regulations by the authorities hinder the market growth in the forecast period. Lack of awareness in rural areas, lesser accessibility for healthcare indicators in underdeveloped nations and social stigma about cancerous condition among people are the other hindrances for the development of tissue diagnostics market.

The variables, for instance, the expanding cases of cancers, expanding interests in innovative work of new advancements, development of proficient and precise items, developing interest for customized drugs, and undiscovered market potential because of the absence of productive diagnostics tests for non-small lung cancer discovery are relied upon to give potential chances to the development of tissue diagnostics market. The rising number of healthcare centres is probably going to support the interest in the tissue diagnostics market.

Tissue Diagnostics Market, by Technology:

The immunochemistry segment of technology has a higher growth rate in the forecasted period.

Immunochemistry (IHC) is the most widely used technology segment in both Clinical Research and Development for cancer treatment and therapy, resulting in the highest revenue generation in the forecast period. The preference of immunochemistry technology is increasing as it provides differentiation between various types of tumours, unlike the conventional methods, which only detect a very few numbers of tissue structures and proteins of the tumours. Digital pathology is expected to show tremendous growth in the forecast period. The growth is due to increasing usage of whole slide imaging (WSI) by pathologists. The whole slide imaging extracts characteristics of the tumour. It quantifies each element of that character, which will support the cancer diagnosis further and give information about clinical measures for treating the tumour. These aspects are predicted to boost the market in the forecast period.

Tissue Diagnostics Market, by application:

Breast cancer segment is expected to show lucrative growth in the estimated period.

The breast cancer segment is predicted to have the highest growth rate in the forecast period. Inclination in breast cancer globally and an increase in the genetic inheritance is predicted to boost the segment in the forecast period. These factors have caused serious concern among many people resulting in several research initiatives and support from the government and private centres. This will further develop this market and help in the diagnosis of breast cancer. The prostate cancer segment is predicted to have a lucrative growth in the forecast period. The progress in prostate cancer biomarker discovery and advancements in genomic technologies are predicted to boost the segment in the forecast period. Biomarker discovery has led to the development of tissue diagnostic assays and created opportunities for this segmental growth in the forecast period. 

Tissue Diagnostics Market, by End-User:

Hospitals are the major end-user segment in terms of its revenue.

Hospitals are currently dominating in terms of its highest revenue generation. Hospitals have a higher consumption than any other end-user segment due to its utility rate of tissue diagnostic solutions. Physicians are increasingly switching to use of tissue-based diagnostic techniques from the conventional ones because of reduction in the time being consumed when compared to the traditional methods. The growth is due to the increase in agreement models being implemented by the hospitals.

Contract research organizations (CRO) are expected to witness immense growth. These are the organizations that provide research support, manage trails, clinical trial services, and functions of the companies and healthcare services that have a budget constraint. As the research studies in cancer therapy have been increasing drastically over recent years, the demand for service provided by these organizations is also increasing, which will accelerate the growth and revenue of this segment.

Tissue Diagnostics Market, by Region:

In North America, there is a huge inclination in cancer conditions among people, which is expected to create demand for tissue diagnostics in the estimated time.

North America region market has the highest revenue generated in the current market condition. The demand for tissue diagnostics is expected to grow due to certain reasons like the precision medicine initiative implementation in the United States, the adoption of sequencing Technologies, healthcare IT systems, and personalized medicine. Asia-Pacific region is expected to show lucrative growth in the forecast period. Higher accessibility to tissue diagnostic assays by many international companies is predicted to boost the segment in the forecast period. 

Key Players in the Tissue Diagnostics Market:

The key revenue generators in the tissue diagnostics market are Abbott Laboratories, Danaher, Siemens, Merck KGaA, GE Healthcare, Thermo Fisher Scientific Inc., bioMérieux SA, DiaGenic ASA, QIAGEN, Becton, F. Hoffmann-La Roche Ltd., Dickinson and Company, BioGenex, Bio SB, and Agilent Technologies. The market is highly competitive due to the presence of many players of different sizes.

Aspect

Particulars

Historical Market Estimations

  2019-2020

  Base Year for Market Estimation

  2019

  Forecast timeline for Market Projection

  2020-2027

  Geographical Scope

  North America, Europe, Asia-Pacific, LAMEA

  Segmentation by Application

  • Breast Cancer
  • Non-small Cell Lung Cancer
  • Prostate Cancer
  • Gastric Cancer
  • Other Cancers

  Segmentation by End User

  • Hospitals
  • Research Laboratories
  • Pharmaceutical Organizations
  • Contract Research Organizations

  Segmentation by Technology

  • ISH
  • Digital pathology
  • Anatomy pathology
  • Workflow
  • Consumables

  Key Countries Covered

U.S., Germany, France, Canada Spain, China, India, Brazil, Mexico, Japan and South Africa

  Key Companies Profiled

  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Siemens
  • Danaher
  • bioMérieux SA
  • QIAGEN
  • Becton, Dickinson and Company
  • Merck KGaA
  • GE Healthcare

 

 


FREQUENTLY ASKED QUESTIONS?
 

A. F. Hoffmann-La Roche Ltd and Abbott Laboratories are some of the key players in the global tissue diagnostics market.

A. The North American region possesses great investment opportunities for the investors to witness the most promising growth in the future due to incidence in cancerous conditions.

A. Technological advancements, product development, and Global expansion are the strategies opted by the leading players in the market.

A. The immunochemistry technology segment is expected to show greater demand in the forecasted period due to its property of differentiating features of different tumours.

Research Methodology

Purchase Options

Enquire To Buy

Personalize this research

  • Triangulate with your own data
  • Get Data as per your format and defination
  • Get a deeper dive on a specific application, geography, customer or competitor
10% Off on Customization
Contact Us

Customers Also Viewed